obesity treatment with bariatric surgery vs glp-1 receptor agonists Anti-obesity drugs are closing the gap between dieting and | Diet and Nutrition | Prevention The results — the most

If it has Lilly on the box, thats the goal we have. The GLP-1 market has expanded from under $12 billion in 2022 to a roughly $65 billion annualized run rate by mid-2025

This reduction in HbA1c levels translates into improved overall diabetes management and reduced risk of complications

For these reasons, limited treatment options exist for this patient population

Summary: Hair loss from GLP-1 medications is typically temporary telogen effluvium caused by rapid weight loss and nutritional changes, manageable through adequate protein intake, micronutrient optimisation, and moderating weight reduction rate

For those with IBS-D (diarrhoea-predominant IBS), there can be some improvements in bowel urgency and/or frequency

A diverse range of food choices can help prevent common deficiencies often seen in restrictive diets